[InMode First Quarter 2022 Financial Results](index=1&type=section&id=InMode%20First%20Quarter%202022%20Financial%20Results) [Financial Highlights](index=1&type=section&id=First%20Quarter%202022%20Highlights) InMode reported strong Q1 2022 results with 31% revenue growth to $85.9 million and 16% GAAP net income increase Q1 2022 vs Q1 2021 Financial Highlights | Metric (U.S. dollars in thousands, except per share) | Q1 2022 | Q1 2021 | Change YoY | | :--- | :--- | :--- | :--- | | **GAAP Results** | | | | | Revenues | $85,921 | $65,524 | +31% | | Gross Margin | 83% | 85% | -2 p.p. | | Net Income | $30,975 | $26,643 | +16% | | Diluted EPS | $0.36 | $0.31 | +16% | | **Non-GAAP Results** | | | | | Gross Margin | 83% | 85% | -2 p.p. | | Net Income | $34,069 | $29,341 | +16% | | Diluted EPS | $0.40 | $0.34 | +18% | * Record quarterly revenues from consumables and service reached **$14.0 million**, a significant increase of **79%** compared to the first quarter of 2021[6](index=6&type=chunk) * The company's total cash position, including cash, cash equivalents, marketable securities, and short-term bank deposits, was **$399.5 million** as of March 31, 2022[6](index=6&type=chunk) * Minimally invasive and subdermal ablative treatment platforms constituted **80%** of quarterly revenues[6](index=6&type=chunk) [Management Commentary](index=1&type=section&id=Management%20Comments) Management expressed confidence, highlighting supply chain mitigation, reaffirmed 2022 guidance, and ongoing R&D * CEO Moshe Mizrahy stated that 2022 started strongly despite global market uncertainty and that the company successfully mitigated the impact of supply chain challenges and shipment price increases on gross margins[5](index=5&type=chunk) * CTO Dr. Michael Kreindel confirmed continued R&D investment in new features for existing platforms and development in new categories such as women's health, ENT, and ED[7](index=7&type=chunk) * President of North America, Shakil Lakhani, reported record consumable sales, indicating a growing platform utilization rate, and anticipates North America will remain the main revenue contributor[8](index=8&type=chunk) * CMO Dr. Spero Theodorou noted that the innovative EmpowerRF platform is receiving positive feedback, supporting the company's expansion into the women's health market[8](index=8&type=chunk) [Detailed Financial Results](index=2&type=section&id=First%20Quarter%202022%20Financial%20Results) Q1 2022 revenue grew 31% YoY to $85.9 million, with GAAP gross margin slightly decreasing to 83% * Total revenues for Q1 2022 reached **$85.9 million**, a **31%** increase compared to Q1 2021[9](index=9&type=chunk) * Revenues outside the U.S. grew **51%** year-over-year and represented **38%** of total revenues[9](index=9&type=chunk)[10](index=10&type=chunk) * GAAP gross margin for Q1 2022 was **83%**, down from **85%** in Q1 2021, attributed to increased international distributor sales, higher consumable sales, and increased freight costs[11](index=11&type=chunk) * GAAP operating margin was **41%** in Q1 2022, consistent with Q1 2021, while Non-GAAP operating margin was **44%** compared to 45% in Q1 2021[12](index=12&type=chunk) [2022 Financial Outlook](index=3&type=section&id=2022%20Financial%20Outlook) InMode management reiterated its full-year 2022 guidance, projecting revenues of $415-425 million Full Year 2022 Guidance | Metric | Expected Range | | :--- | :--- | | Revenues | $415 million - $425 million | | *Non-GAAP Gross Margin | 84% - 86% | | *Non-GAAP Income from Operations | $199 million - $204 million | | *Non-GAAP Earnings per Diluted Share | $2.06 - $2.11 | [Consolidated Financial Statements](index=5&type=section&id=Consolidated%20Financial%20Statements) This section provides detailed unaudited consolidated financial statements for Q1 2022 [Condensed Consolidated Statements of Income](index=5&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20INCOME) For Q1 2022, InMode reported total revenues of $85.9 million and net income of $31.0 million Condensed Consolidated Statements of Income (Unaudited, U.S. dollars in thousands) | | Three months ended March 31, | | :--- | :--- | :--- | | | **2022** | **2021** | | **REVENUES** | **85,921** | **65,524** | | COST OF REVENUES | 14,772 | 10,079 | | **GROSS PROFIT** | **71,149** | **55,445** | | TOTAL OPERATING EXPENSES | 36,141 | 28,674 | | **INCOME FROM OPERATIONS** | **35,008** | **26,771** | | INCOME BEFORE TAXES | 35,387 | 26,815 | | **NET INCOME ATTRIBUTABLE TO INMODE LTD.** | **30,975** | **26,643** | | **Diluted EPS** | **$0.36** | **$0.31** | [Condensed Consolidated Balance Sheets](index=6&type=section&id=CONDENSED%20CONSOLIDATED%20BALANCE%20SHEETS) As of March 31, 2022, InMode reported total assets of $464.5 million, with cash and equivalents at $399.5 million Condensed Consolidated Balance Sheets (Unaudited, U.S. dollars in thousands) | | March 31, 2022 | December 31, 2021 | | :--- | :--- | :--- | | **TOTAL CURRENT ASSETS** | **454,848** | **470,114** | | **TOTAL ASSETS** | **464,466** | **478,541** | | **TOTAL CURRENT LIABILITIES** | **49,818** | **51,850** | | **TOTAL LIABILITIES** | **61,148** | **62,739** | | **TOTAL SHAREHOLDERS' EQUITY** | **403,318** | **415,802** | | **TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY** | **464,466** | **478,541** | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20CASH%20FLOWS) For Q1 2022, net cash from operations was $31.9 million, with significant cash used in financing activities Condensed Consolidated Statements of Cash Flows (Unaudited, U.S. dollars in thousands) | | Three months ended March 31, | | :--- | :--- | :--- | | | **2022** | **2021** | | **Net cash provided by operating activities** | **31,853** | **24,766** | | Net cash (used in) investing activities | (12,692) | (37,608) | | Net cash provided by (used in) financing activities | (42,476) | 9,028 | | **NET DECREASE IN CASH AND CASH EQUIVALENTS** | **(23,466)** | **(4,037)** | | CASH AND CASH EQUIVALENTS AT END OF PERIOD | 44,670 | 64,901 | [Financial Highlights by Geography, Category, and Technology](index=8&type=section&id=CONDENSED%20CONSOLIDATED%20FINANCIAL%20HIGHLIGHTS) In Q1 2022, the United States accounted for 62% of revenue, with capital equipment and minimally invasive platforms as primary drivers Revenues by Geography (Q1 2022 vs Q1 2021) | Geography | Q1 2022 Revenue (U.S. dollars in thousands) | % of Total | Q1 2021 Revenue (U.S. dollars in thousands) | % of Total | | :--- | :--- | :--- | :--- | :--- | | United States | $53,606 | 62% | $44,065 | 67% | | International | $32,315 | 38% | $21,459 | 33% | | **Total** | **$85,921** | **100%** | **$65,524** | **100%** | Revenues by Category (Q1 2022 vs Q1 2021) | Category | Q1 2022 Revenue (U.S. dollars in thousands) | % of Total | Q1 2021 Revenue (U.S. dollars in thousands) | % of Total | | :--- | :--- | :--- | :--- | :--- | | Capital equipment | $71,943 | 84% | $57,731 | 88% | | Consumables and service | $13,978 | 16% | $7,793 | 12% | | **Total** | **$85,921** | **100%** | **$65,524** | **100%** | [Reconciliation of GAAP to Non-GAAP Statements of Income](index=9&type=section&id=RECONCILIATION%20OF%20GAAP%20CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20INCOME%20TO%20NON-GAAP) This table reconciles GAAP to Non-GAAP financial measures for Q1 2022, primarily adjusting for share-based compensation GAAP to Non-GAAP Reconciliation for Q1 2022 (U.S. dollars in thousands) | | GAAP | Share Based Compensation | Non-GAAP | | :--- | :--- | :--- | :--- | | GROSS PROFIT | 71,149 | 314 | 71,463 | | INCOME FROM OPERATIONS | 35,008 | 3,094 | 38,102 | | NET INCOME ATTRIBUTABLE TO INMODE LTD. | 30,975 | 3,094 | 34,069 | | Diluted EPS | $0.36 | | $0.40 |

Financial Data and Key Metrics Changes - The company reported a record revenue of $110.5 million for Q4 2021, representing a 47% increase year-over-year, and a full-year revenue of $357.6 million, up 73% compared to 2020 [7][18] - Net income for Q4 2021 was $52.7 million on a GAAP basis and $55.2 million on a non-GAAP basis, while full-year net income reached $165 million on a GAAP basis and $176.3 million on a non-GAAP basis [8] - The gross margin for Q4 2021 was 85%, with GAAP operating margin at 49% and non-GAAP operating margin at 51% [24][25] Business Line Data and Key Metrics Changes - Sales of capital equipment accounted for 89% of total revenue in Q4 2021, while consumable and service revenues represented 11% [19] - Revenue from minimally invasive and ablative technologies grew to 73% of total revenue in Q4 2021, up from 65% in the previous year [10] - Sales from consumables and services reached record volumes, with consumables expected to become a more significant part of the revenue mix as the install base grows [9] Market Data and Key Metrics Changes - International sales in Q4 2021 were $36.3 million, a 69% increase year-over-year, and full-year international sales reached $120.3 million, up 112% compared to 2020 [12] - The geographical revenue mix for Q4 2021 was 67% from the U.S. and 33% internationally, compared to 71% and 29% in Q4 2020 [19] Company Strategy and Development Direction - The company plans to continue expanding its install base and launching new platforms, with a focus on minimally invasive technologies [17] - The management emphasized the importance of maintaining a competitive advantage through innovative product offerings and a strong R&D pipeline [71] Management's Comments on Operating Environment and Future Outlook - The management acknowledged challenges posed by COVID-19 variants, particularly in regions like China and Europe, but expressed optimism about returning to normal business operations [14][30] - The company is prepared to manage supply chain challenges and has established multiple suppliers for components to mitigate risks [33][34] Other Important Information - The company ended 2021 with a strong balance sheet, holding $415.9 million in cash and cash equivalents [26] - The management indicated plans for share repurchases and potential M&A opportunities, although no suitable targets have been identified yet [70] Q&A Session Summary Question: Impact of Omicron on Q1 and future outlook - Management noted some countries are experiencing lockdowns, which may affect sales, particularly in China, but they remain optimistic about recovery in February or March [30][32] Question: Margin management amid supply chain challenges - Management highlighted successful navigation of supply chain issues in 2021 and expressed confidence in maintaining margins despite rising logistics costs [35] Question: Expectations for consumable revenue growth - Management indicated that consumable revenue could grow to 14%-15% of total revenue as the install base increases, with a focus on designing new platforms that require disposables [49][51] Question: Clinical data and Empower platform expectations - Management confirmed expectations for the Empower platform to generate $20 million in revenue for 2022, with encouraging preliminary clinical results [38][42] Question: Reimbursement strategy for Empower - Management is open to exploring reimbursement options in the future but currently sees a strong cash-based business model as advantageous [84][86] Question: Competitive landscape in skin tightening - Management acknowledged competition from established players but emphasized their focus on minimally invasive technologies and maintaining a competitive edge through innovation [90][92]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

Exhibit 99.1 InMode Reports Record Fourth Quarter and Full Year 2021 Financial Results: Quarterly Revenue of $110.5M, 47% Year-Over-Year Growth GAAP Net Income of $52.7M, 46% Increase Compared to Q4 2020 YOKNEAM, Israel, Feb. 10, 2022, InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the fourth quarter and full year ended Dec. 31, 2021. Fourth Quarter 2021 Highlights: Full Year 2021 Highlights: | U.S. ...

InMode Ltd. (NASDAQ:INMD) Q3 2021 Earnings Conference Call October 26, 2021 8:30 AM ET Company Participants Miri Segal - President, MS-IR Moshe Mizrahy - Chairman and CEO Shakil Lakhani - President, North America Yair Malca - CFO Dr. Spero Theodorou - CMO Conference Call Participants Travis Steed - Barclays Matthew Taylor - UBS Kyle Rose - Canaccord Genuity Mike Matson - Needham & Company Jeff Johnson - Robert W. Baird Operator Hello and welcome to the InMode Limited Third Quarter 2021 Earnings Conference C ...

InMode Ltd. (NASDAQ:INMD) Q2 2021 Earnings Conference Call July 28, 2021 8:30 AM ET Company Participants Miri Segal - Investor Relations Moshe Mizrahy - Chairman of Board and Chief Executive Officer Shakil Lakhani - President, North America Yair Malca - Chief Financial Officer Spero Theodorou - Chief Medical Officer Conference Call Participants Travis Steed - Barclays Matt Taylor - UBS Kyle Rose - Canaccord Genuity Mike Matson - Needham & Company Jeff Johnson - Baird Operator Good morning, and welcome to th ...

InMode Ltd (NASDAQ:INMD) Q1 2021 Earnings Conference Call May 5, 2021 8:30 AM ET Company Participants Miri Segal - MS-IR Moshe Mizrahy - Chairman & CEO Shakil Lakhani - President, North America Yair Malca - CFO Spero Theodorou - Chief Medical Officer Conference Call Participants Matt Taylor - UBS Kyle Rose - Canaccord Genuity Asaf Chandali - Oppenheimer Operator Good day, and welcome to the InMode Ltd. First Quarter 2021 Earnings Conference Call. [Operator Instructions]. I would now like to turn the confere ...

InMode Ltd. (NASDAQ:INMD) Q4 2020 Earnings Conference Call February 10, 2021 8:30 AM ET Company Participants Miri Segal - MS, IR Moshe Mizrahy - CEO & Chairman Michael Kreindel - Co-Founder & CTO Yair Malca - CFO Spero Theodorou - CMO Shakil Lakhani - President, North America Rafi Lickerman - VP, Finance Conference Call Participants Matt Taylor - UBS Kyle Rose - Canaccord Jeff Johnson - Baird Asaf Barel Chandali - Oppenheimer Operator Good day and welcome to the InMode Limited Fourth Quarter and Full-Year 2 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 19 ...

Financial Data and Key Metrics Changes - InMode generated record revenue of $59.7 million in Q3 2020, a 49% increase from Q3 2019 [8] - Net income on a GAAP basis was $23.9 million, and on a non-GAAP basis, it was $26.6 million [8] - GAAP diluted earnings per share were $0.57, compared to $0.42 in Q3 2019, while non-GAAP diluted earnings per share were $0.63, up from $0.42 [20] - The company increased its full-year 2020 revenue guidance range to $192 million to $195 million [12] Business Line Data and Key Metrics Changes - Approximately 58% of revenue came from surgical platforms, 35% from hands-free platforms, and 7% from traditional laser and non-invasive RF platforms [8] - International revenue grew 109% year-over-year, driven by marketing and sales activities in various countries [9][17] Market Data and Key Metrics Changes - The company reported strong demand in North America for minimally invasive and hands-free devices, confirming the effectiveness of their sales strategy during the pandemic [13] - The international market doubled year-over-year in Q3, with significant growth in China, Brazil, Mexico, and Korea [44] Company Strategy and Development Direction - InMode plans to introduce two new platforms targeting gynecology, ENT, and ophthalmology markets in 2021 and beyond [11] - The company is committed to investing in R&D, expanding its sales force, and enhancing marketing efforts despite the pandemic [12][27] - A share repurchase program of up to 1 million shares was announced, reflecting confidence in the company's future [21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the continued demand for their technologies, citing a shift in consumer spending towards aesthetic procedures due to reduced travel and entertainment expenses [37] - The company remains focused on maintaining operations and growth despite the ongoing challenges posed by COVID-19 [45] Other Important Information - The company has a strong balance sheet with cash and cash equivalents totaling $234.3 million as of September 30, 2020 [20] - Operating expenses increased by 42.4% year-over-year, primarily due to sales and marketing investments [18] Q&A Session Summary Question: About the commercial organization and growth plans - Management confirmed ongoing investments in R&D and sales force, including expansion in France and China [27] Question: On the share buyback strategy - The company plans to repurchase shares opportunistically, starting with the approved 1 million shares [29] Question: Importance of recent peer-reviewed studies - Management emphasized the role of studies in supporting marketing efforts and differentiating from competitors [31] Question: Insights on market demand and consumer behavior - There is observed pent-up demand for aesthetic procedures, with clinics reporting busier operations than usual [37][41] Question: Update on international market performance - The international market is expected to continue growing, with specific focus on China and South America despite challenges [44][45] Question: Installed base split and platform utilization - Out of 6,400 systems installed worldwide, 3,500 are in the US, with an increase in the number of platforms per office [52] Question: Revenue growth expectations for 2021 - Management indicated that revenue growth trends could continue similarly to previous years, with guidance to be provided in the next earnings call [54]